# Organon & Co.: Form 10-K/A for the period ended Dec 31, 2024

- Company: [Organon & Co.](/companies/ogn.md) (CIK 1821825)
- Form: 10-K/A
- Filed: 2025-11-10
- Accepted by EDGAR: Nov 10, 2025, 06:03 ET
- Period: 2024-12-31
- Accession: 0001104659-25-108693
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1821825/000110465925108693/ogn-20241231x10ka.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1821825/000110465925108693/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2024-01-01 to 2024-12-31 | $6.40bn | us-gaap:Revenues |
| Cost of revenue | 12 months, 2024-01-01 to 2024-12-31 | $2.69bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 12 months, 2024-01-01 to 2024-12-31 | $3.71bn | us-gaap:GrossProfit |
| Selling, general and administrative | 12 months, 2024-01-01 to 2024-12-31 | $1.76bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 12 months, 2024-01-01 to 2024-12-31 | $520.0m | us-gaap:InterestExpense |
| Income tax | 12 months, 2024-01-01 to 2024-12-31 | −$57.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months, 2024-01-01 to 2024-12-31 | $864.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2024-01-01 to 2024-12-31 | $3.33 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months, 2024-01-01 to 2024-12-31 | $3.36 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2024-01-01 to 2024-12-31 | 259,152,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2024-01-01 to 2024-12-31 | $939.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2024-01-01 to 2024-12-31 | $175.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months, 2024-01-01 to 2024-12-31 | $297.0m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | at 2024-12-31 | $675.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2024-12-31 | $4.35bn | us-gaap:AssetsCurrent |
| Total assets | at 2024-12-31 | $13.10bn | us-gaap:Assets |
| Current liabilities | at 2024-12-31 | $2.72bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2024-12-31 | $12.63bn | us-gaap:Liabilities |
| Long-term debt | at 2024-12-31 | $8.86bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2024-12-31 | $20.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2024-12-31 | $472.0m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 82,027 characters.

### CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

We make statements in this Annual Report on Form 10-K, and we may from time to time make other written reports and oral statements, regarding our outlook or expectations for financial, business or strategic matters regarding or affecting us that are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, all of which are based on management’s current expectations and are subject to risks and uncertainties which change over time and may cause results to differ materially from those set forth in the statements. One can identify these forward-looking statements by their use of words such as “anticipates,” “expects,” “plans,” “will,” “estimates,” “forecasts,” “projects,” “believes,” “would,” “potentially,” “intends,” “seeks,” “future,” “might,” “likely,” “target,” “predict,” “continue,” “should,” and other words of similar meaning, or negative variations of any of the foregoing. One can also identify them by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements include, but are not limited to, statements relating to our growth and acquisition strategies, financial results, product development, product approvals, product potential and development programs. One must carefully consider any such statement and should understand that many factors could cause actual results to differ materially from our forward-looking statements. These factors may be based on inaccurate assumptions and are subject to a broad variety of other risks and uncertainties. No forward-looking statement can be guaranteed and actual future results may vary materially. The factors described in Part I. Item 1A. Risk Factors of this report or otherwise described in our filings with the SEC, provide examples of risks, uncertainties and events that may cause our actual results to differ materially from the expectations expressed in our forward-looking statements, including, but not limited to:

- expanded brand and class competition in the markets in which we operate;
- difficulties with performance of third parties we rely on for our business growth;
- the failure of any supplier to provide substances, materials, or services as agreed;
- the increased cost of supply, manufacturing, packaging, and operations;
- difficulties developing and sustaining relationships with commercial counterparties;
- competition from generic products as our products lose patent protection;
- any failure by us to retain market exclusivity to *Nexplanon* or to obtain an additional period of exclusivity in the United States for *Nexplanon* subsequent to the expiration of the rod patents in 2027;
- the continued impact of the September 2024 LOE for *Atozet;*
- disruptions at the FDA, the SEC and other U.S. and comparable government agencies;
- difficulties and uncertainties inherent in the implementation of our acquisition strategy or failure to recognize the benefits of such acquisitions;
- pricing pressures globally, including rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and health care reform, pharmaceutical reimbursement and pricing in general;
- the impact of higher selling and promotional costs;
- changes in government laws and regulations in the United States and other jurisdictions, including laws and regulations governing the research, development, approval, clearance, manufacturing, supply, distribution, and/or marketing of our products and related intellectual property, environmental regulations, and the enforcement thereof affecting our business;
- efficacy, safety or other quality concerns with respect to our marketed products, whether or not scientifically justified, leading to product recalls, withdrawals or declining sales;
- delays or failures to demonstrate adequate efficacy and safety of our product candidates in pre-clinical and clinical trials, which may prevent or delay the development, approval, clearance, or commercialization of our product candidates;
- future actions of third-parties, including significant changes in customer relationships or changes in the behavior and spending patterns of purchasers of health care products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and forgoing health care insurance coverage;
- legal factors, including product liability claims, antitrust litigation and governmental investigations, including tax disputes, environmental claims and patent disputes with branded and generic competitors, any of which could preclude commercialization of products or negatively affect the profitability of existing products;
- lost market opportunity resulting from delays and uncertainties in clinical trials and the approval or clearance process of the US FDA and other regulatory authorities;
- the failure by us or our third party collaborators and/or their suppliers to fulfill our or their regulatory or quality obligations, which could lead to a delay in regulatory approval or commercial marketing of our products;
- cyberattacks on, or other failures, accidents, or security breaches of, our or third-party providers’ information technology systems, which could disrupt our operations and those of third parties upon which we rely;
- increased focus on privacy issues in countries around the world, including the United States, the EU, and China, and a more difficult legislative and regulatory landscape for privacy and data protection that continues to evolve with the potential to directly affect our business, including recently enacted laws in a majority of states in the United States requiring security breach notification;
- changes in tax laws including changes related to the taxation of foreign earnings;
- the impact of any future pandemic, epidemic, or similar public health threat on our business, operations and financial performance;
- loss of key employees or inability to identify and recruit new employees;
- changes in accounting pronouncements promulgated by standard-setting or regulatory bodies, including the Financial Accounting Standards Board and the SEC, that are adverse to us; and
- economic factors over which we have no control, including changes in inflation, interest rates, recessionary pressures, and foreign currency exchange rates.

It is not possible to predict or identify all such factors. Consequently, one should not consider the above list or any other such list to be a complete statement of all potential risks or uncertainties. Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update or revise any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as otherwise may be required by law.

### General

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations as presented in this Amendment is intended to assist the reader in understanding our (i) financial condition and results of operations for the years ended December 31, 2024 and 2023 and (ii) our results of operations for the year ended December 31, 2022 and should be read in conjunction with our Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K to enhance the understanding of our results of operations, financial condition and cash flows. Additionally, this section should be read in connection with Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K”), as revised and included within this report under the section titled “Operating Results—Sales Overview For the Year Ended December 31, 2023 Compared to 2022”. The 2023 Form 10-K has been filed with the SEC and is available on the SEC’s website at www.sec.gov, which includes a discussion regarding our financial condition for the years ended December 31, 2023 and 2022. The Management’s Discussion and Analysis of Financial Condition and Results of Operations in this Amendment amends statements in the Original Form 10-K regarding the sales of *Nexplanon* in the United States that appears in our discussion of our financial condition and results of operations for the years ended December 31, 2024 and 2023 (as relates to *Nexplanon* sales during the third and fourth quarters of 2024) and our discussion of the results of operations for the years ended December 31, 2023 and 2022 (as relates to *Nexplanon* sales during the fourth quarter of 2022).

We are a global healthcare company with a primary focus on improving the health of women throughout their lives. We develop and deliver innovative health solutions through a portfolio of prescription therapies and medical devices within women’s health, biosimilars and established brands. We have a portfolio of more than 70 medicines and products across a range of therapeutic areas. We sell these products through various channels including drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. We operate six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom. Unless otherwise indicated, trademarks appearing in italics throughout this document are trademarks of, or are used under license by our companies.

### Key Trends Affecting Our Results of Operations

- *Generic Competition*: Except for *Emgality, Rayvow* and *Vtama*, our established brands products are beyond market exclusivity. Although these products continue to represent a valuable opportunity to generate significant operating profit relative to low promotional and development expenses, they are subject to competition from generic versions of these products. For instance, we have been negatively impacted by the September 2024 LOE for *Atozet*, and we expect those negative impacts to continue or intensify in 2025. In addition, *Nexplanon* is an important Organon brand that continues to have good market exclusivity, especially in the United States. This complex drug-device combination has different components with different patent exclusivities. In the United States, patents claiming key aspects of the *Nexplanon* applicator will expire in 2030 and patents for the *Nexplanon* rod will expire in late 2027. Patents for the majority of countries where *Nexplanon* is commercialized outside the United States will expire between 2025 and 2026. See Note 18 “Contingencies—Other Matters” to the Consolidated Financial Statements in this report.
- *Historical Shift Towards Long-Acting Reversible Contraceptives:* Daily contraceptive pills are by far the largest contraception market segment, with almost half of all women choosing a hormonal contraceptive electing this particular method. However,

the Long-Acting Reversible Contraceptives (“LARC”) market, including *Nexplanon*, is expected to continue to be an important and large segment of the overall contraceptive market. Despite an increasingly diverse market of contraception methods (including the over-the-counter birth control pill), payors, providers, and patients continue to believe in the benefits of long-acting and highly effective options such as *Nexplanon.*

- *Increased Access to Fertility Solutions*: With the global trend toward declining birthrates, governments and payors are implementing favorable policies across major markets that, in turn, improve access to care and drives growth for infertility therapies.
- *Growing Acceptance of Biosimilars*: The market for biologics continues to experience strong growth trends. Given the high cost of many of these biologics treatments, biosimilars are a more affordable alternative and represent a significant opportunity for patients, providers, and payors once a biologics product loses patent protection. Moreover, a significant number of biologics are expected to lose exclusivity over the next decade, representing a large opportunity for more biosimilar approvals.
- *Increased Competitive Pressures*: The markets in which we conduct our business and the pharmaceutical industry in general are highly competitive and highly regulated. Our competitors include other worldwide research-based pharmaceutical companies, smaller research companies with more limited therapeutic focus and generic drug manufacturers.

### Recent Developments

### Business Development

### Dermavant Sciences Ltd. (“Dermavant”)

On October 28, 2024, we acquired Dermavant, a company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. Dermavant’s novel product, *Vtama*, for the topical treatment of mild, moderate, and severe plaque psoriasis in adults, was approved by the U.S. Food and Drug Administration (the “FDA”) in May 2022. In December 2024, the FDA approved *Vtama* for the treatment of atopic dermatitis, also known as eczema, in adults and children two years of age and older. Atopic dermatitis is one of the most common inflammatory dermatological conditions in adults, presenting a higher disease burden for women compared to men. The acquisition allows us to further expand our existing portfolio of established brands and biosimilar dermatology treatments.

Consideration for Dermavant consists of the upfront payment of $175 million and a $75 million milestone payment upon regulatory approval, as well as payments of up to $950 million for the achievements of certain commercial milestones, tiered royalties on net sales, and the assumption of liabilities, including certain debt obligations, which were accounted for at fair value on the acquisition date.

During the fourth quarter of 2024, the regulatory milestone related to *Vtama’s* atopic dermatitis indication, which was recorded as part of contingent consideration at fair value, was achieved and recorded in *Accrued and other current liabilities.* In January 2025, we paid $75 million related to the milestone.

In the fourth quarter of 2024, we recognized an additional intangible asset of $24 million, related to a sales-based milestone that was deemed probable and was related to an assumed licensing agreement. The intangible asset will be amortized over 11 years.

### Suzhou Centergene Pharmaceuticals (“Centergene”)

In September 2024, we entered into license and supply agreements with Centergene, pursuant to which we acquired the exclusive commercialization rights to Centergene’s investigational asset, SJ02, in China. SJ02 is a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal peptide fusion protein (FSH-CTP) designed for controlled ovarian stimulation (“COS”) in combination with a GnRH antagonist. It is used to facilitate the development of multiple follicles in women undergoing ART programs. Under the terms of the agreement, we will pay $12 million, of which $6 million was paid in the fourth quarter of 2024. In addition, the remaining $6 million is payable upon obtaining the manufacturing license, which is refundable if thereafter either the regulatory approval is not obtained or marketing authorization cannot be transferred. We may owe additional regulatory and sales-based milestones to Centergene of up to $170 million under the terms of the license and supply agreements. We will recognize regulatory and sales-based milestones when the achievement is probable.

### Eli Lilly (“Lilly”)

In December 2023, we announced an agreement with Lilly to become the sole distributor and promoter of the migraine medicines *Emgality* and *Rayvow* in Europe. Lilly will remain the marketing authorization holder and will manufacture the products for sale. Under the terms of the agreement, we paid an upfront payment of $50 million upon closing of the transaction in January 2024, and will recognize sales-based milestones when the achievement is deemed probable. In the first quarter of 2024, we recognized an intangible asset of $220 million, comprised of the $50 million upfront payment and $170 million of sales-based milestones that were deemed probable. The intangible asset will be amortized over 10 years.

In August of 2024, we expanded our agreement with Lilly to become the sole distributor and promoter for *Emgality* in the following additional markets: Canada, Colombia, Israel, South Korea, Kuwait, Mexico, Qatar, Saudi Arabia, Taiwan, Turkey, and the United Arab Emirates. We paid an upfront payment of $23 million for the expansion of territory upon closing of the transaction in August 2024, and will recognize sales-based milestones when the achievement is deemed probable. In the third quarter of 2024, we recognized an additional intangible asset of $113 million, comprised of the $23 million upfront payment and $90 million related to the sales-based milestones that were deemed probable. The intangible asset will be amortized over 10 years.

As of December 31, 2024, we had accrued $20 million in *Accrued and Other current liabilities* and $240 million in *Other noncurrent liabilities* in total related to the probable sales-based milestones. In January 2025, we paid $20 million related to the milestones.

### Operating Results

### Sales Overview For the Year Ended December 31, 2024 Compared to 2023

*($ in millions)*

| ​ ​ ​ ​ ​ | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2024 | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ 2023 | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​% ​ Change 2024 vs. 2023 | ​ ​ % Change Excluding Foreign Exchange ​ |
| --- | --- | ---: | --- | ---: | ---: | ---: |
| United States | ​ | $1,572 | ​ | $1,478 | 6% | 6% |
| International | ​ | 4,831 | ​ | 4,785 | 1 | 3 ​ |
| Total | ​ | $6,403 | ​ | $6,263 | 2% | 3% |

Worldwide sales were $6.4 billion for the year ended December 31, 2024, an increase of 2%, compared to 2023. Worldwide sales during the year ended December 31, 2024 were negatively impacted by approximately 1%, or $77 million, due to unfavorable foreign exchange.

Excluding foreign exchange, sales increases for the year ended December 31, 2024, primarily reflect the performance of:

- *Nexplanon,* due to increased sales (including an estimated $15 million of sales as of December 31, 2024 resulting from the identified sales practices for wholesalers described in the “Explanatory Note” above, with the impact estimated using average daily sales, inventory levels at the wholesaler and days on hand at the wholesaler), favorable price and discount rates in the United States, increased demand and favorable price in international markets and an increase in demand in our institutional business in Africa;
- *Emgality* and *Rayvow,* due to the acquisition of the distribution and promotion rights from Lilly in 2024 in certain markets outside of the United States;
- *Hadlima,* due to the launch in the United States in July 2023 and a modest increase in international markets; and
- *Diprospan*, due to recovery from the manufacturing issues resulting from the regulatory inspection finding at the Heist manufacturing location that impacted the manufacturing of selected injectable steroid brands in the first quarter of 2023 (the “Market Action”).

This performance was offset by decreases for the year ended December 31, 2024 in:

- *NuvaRing,* due to ongoing generic competition and the negative impact of increased government discount rates in the United States;
- *Atozet,* primarily due to LOE in France, Spain and Japan and the timing of tenders in the Latin America region, partially offset by increased demand in certain markets in Europe, prior to LOE in September 2024;
- *Singulair* due to decreased demand in China and Japan and price decreases in Japan; and
- *Cozaar* and *Hyzaar,* driven by the negative impact of volume-based procurement (“VBP”) in China and unfavorable pricing in Japan.

LOE negatively impacted sales of certain of our products by approximately $57 million during the year ended December 31, 2024, based on the decrease in volume period over period, which was primarily driven by the LOE of *Atozet* in France, Spain, and Japan. VBP in China had a $13 million negative impact on our sales during the year ended December 31, 2024. We expect VBP to continue to impact our established brands product portfolio for the next several quarters.

Our operations include a portfolio of products. Highlights of the sales of our products for the year ended December 31, 2024 and 2023 are provided below. See Note 5 “Product and Geographic Information” to the Consolidated Financial Statements for further details on sales of our products.

### Women’s Health

*($ in millions)*

| ​ ​ ​ ​ ​ | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2024 | ​ ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ 2023 | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ % Change ​ 2024 vs. 2023 | ​ ​ % Change Excluding Foreign Exchange |
| --- | --- | ---: | --- | ---: | ---: | ---: |
| Nexplanon/Implanon NXT | ​ | $963 | ​ | $830 | 16% | 17% |
| NuvaRing (1) | ​ | 115 | ​ | 176 | (35) | (33) ​ |
| Marvelon/Mercilon | ​ | 134 | ​ | 134 | — | 2 ​ |
| Follistim AQ | ​ | 237 | ​ | 262 | (10) | (9) ​ |
| Ganirelix Acetate Injection | ​ | 109 | ​ | 110 | (1) | 1 ​ |
| Jada | ​ | 61 | ​ | 43 | 40 | 40 ​ |

*(1) Sales of the authorized generic version of* ***NuvaRing*** *were previously included in Other Women’s Health.*

### Contraception

Worldwide sales of *Nexplanon,* a single-rod subdermal contraceptive implant, increased 16% for the year ended December 31, 2024, compared to 2023, primarily due to increased sales, favorable price and discount rates in the United States, increased demand and favorable price in international markets and an increase in demand in our institutional business in Africa. The increased sales for *Nexplanon* included an estimated $15 million as of December 31, 2024 resulting from the identified sales practices for wholesalers described in the “Explanatory Note” above. The impact was estimated using average daily sales, inventory levels at the wholesaler and days on hand at the wholesaler.

Worldwide sales of *NuvaRing*, a vaginal contraceptive product, declined 35% for the year ended December 31, 2024, compared to 2023, due to ongoing generic competition and the negative impact of increased government discount rates in the United States. We expect a continued decline in *NuvaRing* sales as a result of generic competition.

Worldwide sales of *Marvelon* and *Mercilon*, combined oral hormonal daily contraceptive pills not approved or marketed in the United States, but available in certain countries outside the United States, remained consistent for the year ended December 31, 2024, compared to 2023, as a result of increased demand in various international markets offset by slight declines in China and Japan.

### Fertility

Worldwide sales of *Follistim AQ*, a fertility treatment, declined 10% for the year ended December 31, 2024, compared to 2023, due to a one-time buy-in as a result of our exit from our interim operating model agreement in the United States with Merck, during the fourth quarter of 2023, and unfavorable discount rates in the United States, partially offset by increased demand in the United States and launches in various international markets.

Worldwide sales of ganirelix acetate injection, a fertility treatment, declined 1% for the year ended December 31, 2024, compared to 2023, primarily due to generic competition, partially offset by increased demand in the United States and various international markets.

### Other Women’s Health

Worldwide sales of *Jada,* a device intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted, increased 40% for the year ended December 31, 2024, compared to 2023. The sales increase is due to continued uptake in the United States following the *Jada* launch in early 2022.

### Biosimilars

*($ in millions)*

| ​ ​ ​ ​ ​ | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2024 | ​ ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ 2023 | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ % Change ​ 2024 vs. 2023 | ​ ​ % Change Excluding Foreign Exchange |
| --- | --- | ---: | --- | ---: | ---: | ---: |
| Renflexis | ​ | $274 | ​ | $278 | (1)% | (1)% |
| Ontruzant | ​ | 141 | ​ | 155 | (9) | (9) ​ |
| Brenzys | ​ | 77 | ​ | 73 | 6 | 6 ​ |
| Hadlima | ​ | 142 | ​ | 44 | 224 | 225 ​ |

*Renflexis* is a biosimilar to *Remicade2* (infliximab) for the treatment of certain autoimmune conditions. Sales declined 1% for the year ended December 31, 2024, compared to 2023, primarily due to unfavorable discount rates in the United States partially offset by demand growth in the United States and Canada. We have commercialization rights to *Renflexis* in countries outside of Europe, Korea, China, Turkey, and Russia.

*Ontruzant* is a biosimilar to *Herceptin2* (trastuzumab) for the treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Sales for the year ended December 31, 2024, compared to 2023, declined 9%, driven by lower demand in the United States and Europe partially offset by increased demand as a result of tenders in Brazil. We have commercialization rights to *Ontruzant* in all countries except in Korea and China.

*Brenzys* is a biosimilar to *Enbrel2* (etanercept) for the treatment of certain inflammatory diseases. Sales for the year ended December 31, 2024, compared to 2023, increased 6%, driven by increased demand in Canada. We have commercialization rights to *Brenzys* in countries outside of the United States, Europe, Korea, China, and Japan.

*Hadlima* is a biosimilar to *Humira2* (adalimumab) for the treatment of certain autoimmune and autoinflammatory conditions. We have commercialization rights to *Hadlima* in countries outside of the EU, Korea, China, Turkey, and Russia. We recorded sales of $142 million during the year ended December 31, 2024, reflecting an increase due to the launch in the United States in July 2023 and a modest increase in international markets. *Hadlima* is currently approved in the United States, Australia, Canada, and Israel.

### Established Brands

Established brands represents a broad portfolio of well-known brands, which generally are beyond market exclusivity, including leading brands in cardiovascular, respiratory, dermatology and non-opioid pain management, for which generic competition varies by market.

### Cardiovascular

*($ in millions)*

| ​ ​ ​ ​ ​ | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2024 | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ 2023 | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ % Change ​ 2024 vs. 2023 | ​ ​ % Change Excluding Foreign Exchange |
| --- | --- | ---: | --- | ---: | ---: | ---: |
| Zetia/Vytorin (1) | ​ | $425 | ​ | $451 | (6)% | (4)% |
| Atozet | ​ | 473 | ​ | 519 | (9) | (8) ​ |
| Cozaar/Hyzaar | ​ | 243 | ​ | 281 | (14) | (11) ​ |

*(1) Sales of the authorized generic version of* ***Zetia*** *were previously included in Other Cardiovascular.*

Combined global sales of *Zetia* and *Vytorin*, medicines for lowering LDL cholesterol, declined 6% for the year ended December 31, 2024, compared to 2023, primarily driven by the decrease in demand and mandatory annual price reductions in Japan, partially offset by increased demand in China.

Sales of *Atozet*, a medicine for lowering LDL cholesterol, declined 9% for the year ended December 31, 2024, compared to 2023, primarily due to LOE in France, Spain, and Japan and the timing of tenders in the Latin America region partially offset by increased demand in certain markets in Europe. We anticipate a continued significant decline in sales of *Atozet* in 2025 due to LOE, which occurred late in the third quarter of 2024, in certain markets in Europe.

Combined global sales of *Cozaar* and *Hyzaar*, medicines for the treatment of hypertension, declined 14% for the year ended December 31, 2024, compared to 2023, driven by the negative impact of VBP in China and mandatory annual price reductions in Japan.

### Respiratory

*($ in millions)*

| ​ ​ ​ ​ ​ | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2024 | ​ ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ 2023 | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ % Change ​ 2024 vs. 2023 | ​ ​ % Change Excluding Foreign Exchange |
| --- | --- | ---: | --- | ---: | ---: | ---: |
| Singulair | ​ | $359 | ​ | $404 | (11)% | (8)% |
| Nasonex (1) | ​ | 276 | ​ | 266 | 4 | 6 ​ |
| Dulera | ​ | 203 | ​ | 194 | 5 | 5 ​ |

*(1) Sales of the authorized generic version of* ***Nasonex*** *were previously included in Other Respiratory.*

Worldwide sales of *Singulair*, a once-a-day oral medicine for the chronic treatment of asthma and for the relief of symptoms of allergic rhinitis, decreased 11% for the year ended December 31, 2024, compared to 2023, due to decreased demand in China and Japan and mandatory annual price reductions in Japan.

Global sales of *Nasonex*, an inhaled nasal corticosteroid for the treatment of nasal allergy symptoms, increased 4% for the year ended December 31, 2024, compared to 2023, respectively, due to increased demand across international markets.

Global sales of *Dulera*, which is also marketed as *Zenhale* in certain markets outside of the United States, a combination medicine for the treatment of asthma, increased 5% for the year ended December 31, 2024, compared to 2023, primarily due to the favorable impact of increased demand in the United States and Canada.

### Non-Opioid Pain, Bone and Dermatology

*($ in millions)*

| ​ ​ ​ ​ ​ | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2024 | ​ ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ 2023 | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ % Change ​ 2024 vs. 2023 | ​ ​ % Change Excluding Foreign Exchange |
| --- | --- | ---: | --- | ---: | ---: | ---: |
| Arcoxia | ​ | $270 | ​ | $257 | 5% | 7% |
| Diprospan | ​ | 139 | ​ | 91 | 52 | 55 ​ |
| Vtama | ​ | 12 | ​ | — | \* | \* ​ |

#### \* Calculation not meaningful.

Sales of *Arcoxia*, a medicine for the treatment of arthritis and pain, increased 5% for the year ended December 31, 2024, compared to 2023, primarily due to increased demand in China and favorable pricing in the Asia Pacific region partially offset by a decrease in demand in various international markets.

Sales of *Diprospan*, a corticosteroid approved for treatment of a wide range of inflammatory conditions, increased 52% for the year ended December 31, 2024, compared to 2023, due to recovery from the manufacturing issues resulting from the Market Action. In the first quarter of 2023, we resolved the regulatory inspection findings.

Sales of *Vtama* a cream for the topical treatment of mild, moderate, and severe plaque psoriasis in adults were $12 million for the year ended December 31, 2024, reflecting the acquisition of Dermavant in the fourth quarter of 2024.

### Other

*($ in millions)*

| ​ ​ ​ ​ ​ | ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2024 | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ 2023 | ​ ​ ​ ​ ​ ​ ​ % Change 2024 vs. 2023 | ​ ​ ​ ​ | ​ % Change Excluding Foreign Exchange |
| --- | --- | ---: | --- | ---: | ---: | --- | ---: |
| Emgality/Rayvow | ​ | $107 | ​ | $— | \* | ​ | \* |
| Proscar | ​ | 95 | ​ | 97 | (2) | ​ | — |

#### \* Calculation not meaningful.

Sales of *Emgality* and *Rayvow* were $107 million for the year ended December 31, 2024, reflecting the acquisition of the distribution and promotion rights from Lilly in 2024, in certain markets outside of the United States.

Worldwide sales of *Proscar*, a medicine for the treatment of symptomatic benign prostate enlargement, declined 2% for the year ended December 31, 2024, compared to 2023, due to decreased demand in China.

### Gross Profit, Expenses and Other For the Year Ended December 31, 2024 Compared to 2023

*($ in millions)*

| ​ ​ | ​ ​ | ​ ​ Year Ended December 31, 2024 | ​ | ​ ​ 2023 | ​ ​ | ​ ​ % Change ​ 2024 vs. 2023 |
| --- | --- | --- | --- | --- | --- | ---: |
| Cost of sales | ​ | $2,688 | ​ | $2,515 | ​ | 7% |
| Gross profit | ​ | ​ 3,715 | ​ | ​ 3,748 | ​ | (1) |
| Selling, general and administrative | ​ | ​ 1,760 |  | ​ 1,893 |  | (7) ​ |
| Research and development | ​ | ​ 469 |  | ​ 528 |  | (11) ​ |
| Acquired in-process research and development and milestones | ​ | ​ 81 |  | ​ 8 |  | \* ​ |
| Restructuring costs | ​ | ​ 31 |  | ​ 62 |  | (50) ​ |
| Interest expense | ​ | ​ 520 |  | ​ 527 |  | (1) ​ |
| Exchange losses | ​ | ​ 26 |  | ​ 42 |  | (38) ​ |
| Other expense, net | ​ | ​ 21 |  | ​ 15 |  | 40 ​ |

#### \* Calculation not meaningful.

### Cost of Sales

Cost of sales increased 7% for the year ended December 31, 2024, compared to 2023, primarily due to higher sales volume, higher inflation impacts to material and distribution costs and amortization of $7 million associated with the inventory fair value adjustment related to the Dermavant acquisition purchase accounting, partially offset by foreign exchange translation. Cost of sales includes amortization of intangible assets which totaled $145 million in 2024, $116 million in 2023 and $116 million in 2022. Amortization for 2024, includes $6 million related to the Dermavant acquired intangibles.

### Gross Profit

Gross profit decreased 1% for the year ended December 31, 2024, compared to 2023, due to the impact of unfavorable price, foreign exchange translation and higher inflation impacts to material and distribution costs partially offset by increased sales due to volume.

### Selling, General and Administrative

Selling, general and administrative expenses decreased 7% for the year ended December 31, 2024, compared to 2023, due to the $80 million charge in 2023 related to the Microspherix legal matter (as discussed in Note 18 “Contingencies” to the Consolidated Financial Statements in this report) and lower costs associated with the implementation of our Enterprise Resource Planning (“ERP”) system, partially offset by increased expenses related to the Dermavant acquisition, including transaction costs of $12 million.

### Research and Development

Research and development expenses decreased 11% for the year ended December 31, 2024, compared to 2023, primarily due to a decrease in clinical study activity and lower personnel costs due to a reduction in headcount related to our restructuring initiatives.

### Acquired In-Process Research and Development and Milestones

For the year ended December 31, 2024, acquired in-process research and development and milestones of $81 million primarily represent the research and development milestones of $70 million for our agreement with Henlius and $10 million for our agreement with Cirqle, which were determined to be probable of being achieved. For the year ended December 31, 2023 acquired in-process research and development and milestones of $8 million represent the upfront and development milestones related to the Claria transaction. See Note 3 “Acquisitions and Licensing Arrangements” to the Consolidated Financial Statements included elsewhere in this report for further information regarding our agreements with Henlius and Cirqle.

### Restructuring Costs

For the year ended December 31, 2024, we incurred $31 million of headcount-related restructuring expense related to the ongoing optimization of our internal operations, primarily the research and development function. During the first quarter of 2025, we implemented additional restructuring initiatives that will drive operational efficiencies in 2025, and will result in an approximate 5% headcount reduction.

### Interest Expense

Interest expense decreased 1% for the year ended December 31, 2024, compared to 2023, reflecting lower interest rates as a result of refinancing a portion of our long-term debt and the impact of our cross-currency swaps, partially offset by interest related to the debt acquired as part of the Dermavant acquisition and approximately $6 million in debt issuance costs related to the refinancing of our long-term debt. Beginning in May 2024, the difference between the interest rate received of 7.3125% and paid of 5.8330% under the cross-currency swap agreements is recorded in *Interest expense.*

### Exchange Losses

Exchange losses decreased 38% for the year ended December 31, 2024, compared to 2023, driven by less volatility in foreign exchange compared to the prior year and the favorable changes in spot rates of our forward contracts.

### Other Expense, net

Other expense increased 40% for the year ended December 31, 2024, compared to 2023, due to the fair value adjustment of contingent consideration related to the Dermavant acquisition.

### Taxes on Income

The effective income tax rate was (7.1)% and (52.2)% for the year ended December 31, 2024 and 2023, respectively. The effective income tax rate reflects the beneficial impact of foreign earnings, offset by the impact of U.S. inclusions under the Global Intangible Low-Taxed Income regime and a partial valuation allowance recorded against non-deductible U.S. interest expense. There was a favorable impact to the 2024 effective tax rate, which was driven by the favorable closure of two non-U.S. tax audits and a return to provision adjustment for the Switzerland entity.

In the third quarter of 2024, the Swiss tax authority confirmed to us the applicable useful life of an existing tax asset. As a result, we have now concluded it is more likely than not we will utilize the entirety of the tax asset. As such, we released a $210 million related valuation allowance.

Effective January 1, 2024, multiple jurisdictions, most notably, a majority of the European Union member states, implemented the Organization for Economic Co-operation and Development’s Pillar 2 global corporate minimum tax rate of 15% on companies with revenues of at least €750 million. We have evaluated the impact of this for 2024 and it does not have a material effect on a full year basis.

### Sales Overview For the Year Ended December 31, 2023 Compared to 2022

*($ in millions)*

| ​ ​ ​ ​ ​ | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2023 | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ 2022 | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ % Change ​ 2023 vs. 2022 | ​ ​ % Change Excluding ​ Foreign ​ Exchange ​ |
| --- | --- | ---: | --- | ---: | --- | ---: | ---: |
| United States | ​ | $1,478 | ​ | $1,437 | ​ | 3% | 3% |
| International | ​ | ​ 4,785 | ​ | ​ 4,737 | ​ | 1 ​ | 4 |
| Total | ​ | $6,263 | ​ | $6,174 | ​ | 1% | 3% |

Worldwide sales were $6.3 billion for the year ended December 31, 2023, an increase of 1% compared with 2022. Worldwide sales were negatively impacted by approximately 2%, or $117 million, due to unfavorable foreign exchange.

Excluding foreign exchange, sales increases primarily reflect the performance of:

- *Atozet* due to increased demand in various international markets;
- *Renflexis* driven primarily by continued patient growth in the United States and Canada;
- *Follistim AQ* due to a one-time buy-in as a result of the exit of the IOM in the United States, increased patient demand in the United States and volume recovery in China related to the COVID-19 negative impact during the first half of the year;
- *Ontruzant* driven by the timing of tenders and increased demand;
- *Jada* due to continued uptake in the United States following the launch; and
- *Marvelon* and *Mercilon,* resulting from the transaction with Bayer Healthcare where we gained rights in China during the second quarter of 2022 and in Vietnam during the third quarter of 2022.

This performance was offset by decreased sales of:

- *Zetia* and *Vytorin* driven by the negative impact of VBP in China;
- the impact of the *Diprospan* regulatory inspection finding at the Heist manufacturing location that impacted the manufacturing of selected injectable steroid brands in the first quarter of 2023 (the “Market Action”); and
- decreased sales of *Cozaar* and *Hyzaar* (a combination of losartan potassium and hydrochlorothiazide that is marketed in Japan as *Preminent™),* primarily due to ongoing generic competition.

The loss of exclusivity negatively impacted sales of certain of our products by approximately $18 million during the year ended December 31, 2023, compared to the year ended December 31, 2022, due to the decrease in volume period over period, which mainly impacted *NuvaRing* in the United States. VBP in China had a $95 million negative impact on our sales during the year ended December 31, 2023, compared to the year ended December 31, 2022. We expect VBP to impact our established brands product portfolio for the next several quarters.

Our operations include a portfolio of products. Highlights of the sales of our products for the year ended December 31, 2023 and 2022 are provided below. See Note 6 “Product and Geographic Information” to the Consolidated Financial Statements for further details on sales of our products.

### Women’s Health

*($ in millions)*

| ​ ​ ​ ​ ​ | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2023 | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ 2022 | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ % Change ​ 2023 vs. 2022 | ​ ​ % Change Excluding Foreign Exchange ​ |
| --- | --- | ---: | --- | ---: | ---: | ---: |
| Nexplanon/Implanon NXT | ​ | $830 | ​ | $834 | (1)% | 1% |
| NuvaRing (1) | ​ | 176 | ​ | 219 | (19) | (18) ​ |
| Marvelon/Mercilon | ​ | 134 | ​ | 110 | 22 | 24 ​ |
| Follistim AQ | ​ | 262 | ​ | 229 | 14 | 16 ​ |
| ganirelix acetate injection | ​ | 110 | ​ | 123 | (10) | (8) ​ |
| Jada | ​ | 43 | ​ | 20 | 113 | 113 ​ |

*(1) Sales of the authorized generic version of* ***NuvaRing*** *were previously included in Other Women’s Health.*

### Contraception

Worldwide sales of *Nexplanon,* a single-rod subdermal contraceptive implant, declined 1% for the year ended December 31, 2023, compared to 2022, primarily due to the impact of foreign exchange, unfavorable discount rates, the result of distributor purchasing patterns associated with the timing of the increase in *Nexplanon* list price in the United States and the impact of the limited participation of a tender in Mexico. This was partially offset by price increases. *Nexplanon* sales as of December 31, 2022 included an estimated $23 million from the identified sales practices for wholesalers described in the “Explanatory Note” above, and a wholesaler buy-in prior to a *Nexplanon* price increase. The impact was estimated using average daily sales, inventory levels at the wholesaler and days on hand at the wholesaler.

Worldwide sales of *NuvaRing*, a vaginal contraceptive product, declined 19% for the year ended December 31, 2023, compared to 2022, due to ongoing generic competition in the United States. We expect a continued decline in *NuvaRing* sales as a result of generic competition.

Worldwide sales of *Marvelon* and *Mercilon*, combined oral hormonal daily contraceptive pills not approved or marketed in the United States but available in certain countries outside the United States, increased 22% for the year ended December 31, 2023, compared to 2022, as a result of the transaction with Bayer Healthcare where we gained rights in China during the second quarter of 2022 and in Vietnam during the third quarter of 2022.

### Fertility

Worldwide sales of *Follistim AQ*, a fertility treatment, increased 14% for the year ended December 31, 2023, compared to 2022, due to a one-time buy-in as a result of the exit of the IOM in the United States, increased patient demand in the United States and volume recovery in China related to the COVID-19 negative impact during the first half of the year. This was partially offset by the negative impact of unfavorable discount rates in the United States.

Worldwide sales of ganirelix acetate injection, a fertility treatment, declined 10% for the year ended December 31, 2023, compared to 2022, primarily due to unfavorable discount rates in the United States and increased generic competition in Europe.

### Other Women’s Health

Worldwide sales of *Jada,* a device intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted, increased 113% for the year ended December 31, 2023, compared to 2022. The sales increase is due to continued uptake in the United States following the *Jada* launch in early 2022.

### Biosimilars

*($ in millions)*

| ​ ​ ​ ​ ​ | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2023 | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ 2022 | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ % Change ​ 2023 vs. 2022 | ​ ​ % Change Excluding Foreign Exchange ​ |
| --- | --- | ---: | --- | ---: | ---: | ---: |
| Renflexis | ​ | $278 | ​ | $226 | 23% | 24% |
| Ontruzant | ​ | 155 | ​ | 122 | 28 | 27 ​ |
| Brenzys | ​ | 73 | ​ | 75 | (2) | 1 ​ |
| Hadlima | ​ | 44 | ​ | 19 | 125 | 130 ​ |

*Renflexis* is a biosimilar to *Remicade* (infliximab) for the treatment of certain inflammatory diseases. Sales increased 23% for the year ended December 31, 2023, compared to 2022, driven primarily by continued demand growth in the United States and Canada. We have commercialization rights to *Renflexis* in countries outside Europe, Korea, China, Turkey, and Russia.

*Ontruzant* is a biosimilar to *Herceptin* (trastuzumab) for the treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Sales for the year ended December 31, 2023, compared to 2022, increased 28% driven by the timing of tenders in Brazil and increased demand partially offset by the competitive pressures in Europe. We have commercialization rights to *Ontruzant* in countries outside of Korea and China.

*Brenzys* is a biosimilar to *Enbrel* (etanercept) for the treatment of certain inflammatory diseases. Sales in the year ended December 31, 2023, compared to 2022, remained substantially consistent. We have commercialization rights to *Brenzys* in countries outside of the United States, Europe, Korea, China, and Japan.

*Hadlima* is a biosimilar to *Humira* (adalimumab) for the treatment of certain inflammatory diseases. We have commercialization rights to *Hadlima* in countries outside of the EU, Korea, China, Turkey, and Russia. We recorded sales of $44 million during the year ended December 31, 2023, reflecting an increase from modest sales during 2022 in markets outside of the United States and the launch in the United States in July 2023. *Hadlima* is currently approved in the United States, Australia, Canada, and Israel.

### Established Brands

Established brands represents a broad portfolio of well-known brands, which generally are beyond market exclusivity, including leading brands in cardiovascular, respiratory, dermatology and non-opioid pain management, for which generic competition varies by market.

### Cardiovascular

*($ in millions)*

| ​ ​ ​ ​ ​ | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2023 | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ 2022 | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ % Change ​ 2023 vs. 2022 | ​ ​ % Change Excluding Foreign Exchange ​ |
| --- | --- | ---: | --- | ---: | ---: | ---: |
| Zetia/Vytorin (1) | ​ | $451 | ​ | $500 | (10)% | (8)% |
| Atozet | ​ | 519 | ​ | 457 | 14 | 13 ​ |
| Cozaar/Hyzaar | ​ | 281 | ​ | 323 | (13) | (9) ​ |

*(1) Sales of the authorized generic version of* ***Zetia*** *were previously included in Other Cardiovascular.*

Combined global sales of *Zetia* and *Vytorin*, medicines for lowering LDL cholesterol, declined 10% for the year ended December 31, 2023, compared to 2022, primarily driven by the negative impact of VBP in China.

Sales of *Atozet*, a medicine for lowering LDL cholesterol, increased 14% for the year ended December 31, 2023, compared to 2022, primarily due to increased demand in various international markets.

Combined global sales of *Cozaar* and *Hyzaar*, medicines for the treatment of hypertension, declined 13% for the year ended December 31, 2023, compared to 2022, primarily due to ongoing generic competition.

### Respiratory

*($ in millions)*

| ​ ​ ​ ​ ​ | ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2023 | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ 2022 | ​ ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ % Change ​ 2023 vs. 2022 | ​ ​ % Change ​ Excluding ​ Foreign ​ Exchange |
| --- | --- | --- | --- | --- | --- | ---: | ---: |
| Singulair | ​ | $404 | ​ | $411 | ​ | (2)% | 3% |
| Nasonex (1) | ​ | ​ 266 | ​ | ​ 260 | ​ | 2 ​ | 6 |
| Dulera |  | ​ 194 |  | ​ 180 |  | 8 | 9 ​ |

*(1) Sales of the authorized generic version of* ***Nasonex*** *were previously included in Other Respiratory.*

Worldwide sales of *Singulair*, a once-a-day oral medicine for the chronic treatment of asthma and for the relief of symptoms of allergic rhinitis, declined 2% for the year ended December 31, 2023, compared to 2022, due to the impact of foreign exchange partially offset by increased demand due to higher incidences of respiratory conditions across many international markets during the fourth quarter of 2023 compared to 2022.

Global sales of *Nasonex*, an inhaled nasal corticosteroid for the treatment of nasal allergy symptoms, increased 2% for the year ended December 31, 2023, compared to 2022, due to increased demand across several markets partially offset by a $10 million milestone related to a regulatory approval received during the first quarter of 2022.

Global sales of *Dulera*, a combination medicine for the treatment of asthma, increased 8% for the year ended December 31, 2023, compared to 2022, primarily due to the favorable impact from price and increased demand in the United States.

### Non-Opioid Pain, Bone and Dermatology

*($ in millions)*

| ​ ​ ​ ​ ​ | ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2023 | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ 2022 | ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ % Change ​ 2023 vs. 2022 | ​ ​ % Change Excluding Foreign Exchange |
| --- | --- | ---: | --- | ---: | ---: | ---: |
| Arcoxia | ​ | $257 | ​ | $241 | 7% | 12% |
| Diprospan | ​ | 91 | ​ | 122 | (25) | (22) ​ |

Sales of *Arcoxia*, a medicine for the treatment of arthritis and pain, increased 7% for the year ended December 31, 2023, compared to 2022, primarily due to customers buying patterns and higher demand in various international markets.

Sales of *Diprospan*, a corticosteroid approved for treatment of a wide range of inflammatory conditions, declined 25% for the year ended December 31, 2023, compared to 2022, due to manufacturing issues resulting from the Market Action. In the first quarter of 2023, we resolved the regulatory inspection findings. Sales have not yet recovered. We expect the sales recovery to continue over the next twelve months.

### Other

*($ in millions)*

| ​ ​ ​ ​ ​ | ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2023 | ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ ​ 2022 | ​ ​ ​ ​ ​ | ​ ​ ​ ​ ​ ​ ​ % Change ​ 2023 vs. 2022 | ​ ​ % Change Excluding ​ Foreign ​ Exchange ​ ​ |
| --- | --- | ---: | --- | ---: | --- | ---: | ---: |
| Proscar | ​ | $97 | ​ | $101 | ​ | (3)% | 1% |

Worldwide sales of *Proscar*, a medicine for the treatment of symptomatic benign prostate enlargement, for the year ended December 31, 2023, compared to 2022 were substantially consistent.

### Gross Profit, Expenses and Other For the Year Ended December 31, 2023 Compared to 2022

*($ in millions)*

| ​ ​ | ​ | ​ ​ Year Ended December 31, 2023 | ​ | ​ ​ 2022 | ​ | ​ ​ % Change 2023 vs. 2022 |
| --- | --- | --- | --- | --- | --- | ---: |
| Cost of sales | ​ | $2,515 | ​ | $2,294 | ​ | 10% |
| Gross profit | ​ | ​ 3,748 | ​ | ​ 3,880 | ​ | (3) |
| ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ |
| Selling, general and administrative |  | ​ 1,893 |  | ​ 1,704 |  | 11 ​ |
| Research and development |  | ​ 528 |  | ​ 471 |  | 12 ​ |
| Acquired in-process research and development and milestones |  | ​ 8 |  | ​ 107 |  | (93) ​ |
| Restructuring costs |  | ​ 62 |  | ​ 28 |  | \* ​ |
| Interest expense |  | ​ 527 |  | ​ 422 |  | 25 ​ |
| Exchange losses |  | ​ 42 |  | ​ 11 |  | \* ​ |
| Other expense, net |  | ​ 15 |  | ​ 15 |  | — ​ |

#### \* Calculation not meaningful.

### Cost of Sales

Cost of sales increased 10% for the year ended December 31, 2023, compared to 2022, primarily due to foreign exchange translation, higher employee-related and material and distribution related costs, which increased as a result of inflationary pressures, and product mix. During the year ended December 31, 2022, we recorded a $36 million inventory charge relating to the Market Action and an impairment charge of $9 million related to a product right for a biosimilar product. Cost of sales includes amortization of intangible assets which totaled $116 million in 2023, $116 million in 2022 and $103 million in 2021.

### Selling, General and Administrative

Selling, general and administrative expenses increased 11% for the year ended December 31, 2023, compared to 2022, due to higher employee-related costs, costs incurred in connection with the separation from Merck, which includes the implementation of the enterprise resource planning system, and the $80 million charge related to the Microspherix legal matter as discussed in Note 20. “Contingencies” to the Consolidated Financial Statements. This was partially offset by lower promotional expenses.

### Research and Development

Research and development expenses increased 12% for the year ended December 31, 2023, compared to 2022, primarily due to higher costs associated with our acquisitions of clinical stage assets, increased clinical study activity and higher employee-related costs.

### Acquired In-Process Research and Development and Milestones

For the year ended December 31, 2023, acquired in-process research and development and milestones of $8 million related to the Claria transaction. For the year ended December 31, 2022 acquired in-process research and development and milestones represents the upfront and development milestones related to our research collaboration and license agreement with Cirqle and our agreement with Henlius for the license of certain biosimilar candidates.

### Restructuring Costs

For the year ended December 31, 2023, we incurred $62 million of headcount-related restructuring expense, of which $58 million is due to activities initiated in the fourth quarter related to the ongoing optimization of our internal operations.

### Interest Expense

Interest expense increased 25% for the year ended December 31, 2023, compared to 2022, due to increased interest rates, and debt fees and discounts expensed as part of the prepayment on the U.S. Dollar-denominated term loan and the impact of exchange rates.

### Exchange Losses

For the year ended December 31, 2023, the change in exchange losses was driven by foreign currency exchange translation losses and the impact of the portion of Euro-denominated debt not designated as a net investment hedge in the prior year period.

### Other Expense, net

For the year ended December 31, 2023, other expense, net, remained relatively consistent with the prior year.

### Taxes on Income

The effective income tax rates were (52.2)% and 18.3% for the year ended December 31, 2023 and 2022, respectively. These effective income tax rates reflect the beneficial impact of foreign earnings, offset by the impact of U.S. inclusions under the Global Intangible Low-Taxed Income regime and a partial valuation allowance recorded against non-deductible U.S. interest expense. In the fourth quarter of 2023, we recorded a $476 million tax benefit comprised of a gross benefit of $686 million, net of a $210 million valuation allowance, resulting from the termination of a Swiss tax arrangement. Our valuation allowance was determined based on expected future income and the terms of the remaining tax arrangement.

On August 16, 2022, the United States enacted the Inflation Reduction Act of 2022. Provisions of the bill that relate to tax include the minimum tax on book income, a 1% excise tax on stock buybacks and certain tax incentives to promote clean energy. There are no impacts of the legislation to the 2023 results. We will continue to assess future impacts of this legislation.

### Liquidity and Capital Resources

As of December 31, 2024, we had cash and cash equivalents of $675 million. We have historically generated and expect to continue to generate positive cash flow from operations. Our ability to fund our operations and anticipated capital needs is reliant upon the generation of cash from operations, supplemented as necessary by periodic utilization of our revolving credit facility. Our principal uses of cash in the future will be primarily to fund our operations, working capital needs, capital expenditures, repayment of borrowings, payment of dividends and strategic business development transactions. We believe that our financing arrangements, future cash from operations, and access to capital markets will provide adequate resources to fund our future cash flow needs.

During the second and fourth quarters of 2024, we refinanced a portion of our long-term debt. These transactions extended certain maturity dates, resulted in lower interest rates for certain of our long-term debt and increased the capacity of our revolving credit facility. See Note 12 “Long-Term Debt and Leases” to the Consolidated Financial Statements included elsewhere in this report for further information on our long-term debt transactions.

Working capital is defined as current assets less current liabilities and was $1.6 billion as of December 31, 2024 and December 31, 2023, respectively. Working capital was impacted by our active cash cycle management, including the factoring of receivables and timing of vendor payments.

We have accounts receivable factoring agreements with financial institutions in certain countries. Under these agreements, we have factored $186 million of our accounts receivable as of December 31, 2024.

Net cash provided by operating activities was $939 million for the year ended December 31, 2024, compared to $799 million for the same period in the prior year. The increase in cash provided by operating activities was primarily attributable to our favorable operating performance and cash cycle working capital, partially offset by higher cash taxes paid and higher severance-related payments.

Net cash used in investing activities was $513 million for the year ended December 31, 2024, compared to $260 million for the same period in the prior year, primarily due to the Dermavant acquisition, the $73 million upfront payments related to the agreement with Lilly and the additional $71 million payments related to milestones, partially offset by lower capital spending as a result of the completion of the implementation of our ERP system.

Net cash used in financing activities was $368 million for the year ended December 31, 2024, compared to $569 million for the same period in the prior year. The decrease in cash used in financing activities was driven by the $250 million voluntary prepayment on the U.S. dollar-denominated term loan in the year ended December 31, 2023, compared to a $7.5 million discretionary prepayment on the U.S. dollar-denominated term loan and $38 million of debt issuance costs related to the long-term debt refinancing in the year ended December 31, 2024.

As part of our post-spinoff plan, we have approved an initiative to further optimize our manufacturing and supply network. As part of this initiative, we will continue to separate our supply chain through planned exits from supply agreements from Merck through 2031. This will enable us to redefine our appropriate sourcing strategy, and move to fit-for-purpose supply chains, while focusing on delivering efficiencies. We anticipate we will incur costs associated with this separation, including but not limited to accelerated depreciation, exit premiums and fees, technology transfer costs, stability and qualification batch costs, one-time resourcing costs, regulatory and filing costs, capital investment, and inventory stock bridges.

For the year ended December 31, 2024 and 2023, our combined revenues from Ukraine, Russia and Israel were approximately 2% of total revenues. While we will continue to monitor the impacts of the Ukraine-Russia war and the Hamas-Israel conflict, as of December 31, 2024, our assets in Ukraine, Russia and Israel are not material.

#### Contractual Obligations

Our contractual obligations as of December 31, 2024, which require material cash requirements in the future, consist of contractual milestones, purchase obligations and lease obligations.

Contractual milestones are potential payments based upon the achievement of specified milestones associated with business development transactions. Such milestone payments will only be payable in the event that our collaborative partners achieve contractually defined success-based milestones such as the advancement of the specified research and development programs or the receipt of regulatory approval for the specified compounds or products and/or we reach a sales threshold of the specified compounds or products. The timing of the payments of the contractual milestones are uncertain and the likelihood of achieving the milestones cannot be determined. As of December 31, 2024, total potential payments for contractual milestones are $3.4 billion. Potential amounts to be paid within the next twelve months are $218 million.

Purchase obligations are enforceable and legally binding obligations for purchases of goods and services which include inventory purchase commitments. As of December 31, 2024, total payments due for purchase obligations are $850 million and extend through 2032. Amounts due within the next twelve months are $356 million.

Long-term debt consists of both fixed and variable-rate instruments. As of December 31, 2024, total payments due for debt obligations are $9.0 billion and extend through 2034. Amounts due within the next twelve months are $8 million.

Lease obligations exclude reasonably certain lease renewals that have not yet been executed. As of December 31, 2024, total payments due for lease obligations are $177 million and extend through 2041. Amounts due within the next twelve months are $49 million.

During 2024, we paid cash dividends of $1.12 per share. On February 13, 2025, our Board of Directors declared a quarterly dividend of $0.28 for each issued and outstanding share of our common stock. The dividend is payable on March 13, 2025, to stockholders of record at the close of business on February 24, 2025.

### Critical Accounting Estimates

The audited annual consolidated financial statements are prepared in conformity with U.S. GAAP and, accordingly, include certain amounts that are based on management’s best estimates and judgments. A discussion of accounting estimates considered critical because of the potential for a significant impact on the financial statements due to the inherent uncertainty in such estimates are disclosed below. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates.

#### Revenue Recognition

Our accounting policy for revenue recognition has a substantial impact on reported results and relies on certain estimates. Revenue is recognized following a five-step model: (i) identify the customer contract; (ii) identify the contract’s performance obligation; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation; and (v) recognize revenue when or as a performance obligation is satisfied. Revenue is reduced for gross-to-net sales adjustments discussed below, all of which involve significant estimates and judgment after considering applicable laws and regulations and definitive contractual agreements with private sector and public sector benefit providers. These types of variable consideration are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts. In addition, revenues are recorded net of time value of money discounts if collection of accounts receivable is expected to be in excess of one year. Estimates are assessed each period and adjusted as required to revise information or actual experience.

In the United States, revenue is reduced by sales discounts issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebate amounts owed based upon definitive contractual agreements or legal requirements with private sector (Managed Care) and public sector (Medicaid and Medicare Part D) customers. Additionally, sales are generally made with a limited right of return under certain conditions.

The provision for aggregate customer discounts in the United States covers chargebacks and rebates. We determine the provision for chargebacks based on expected sell-through levels by our wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. We use historical customer segment utilization mix, sales, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued.

We continually monitor our provision for aggregate customer discounts. There were no material adjustments to estimates associated with the aggregate customer discount provision in 2024, 2023, or 2022.

Summarized information about changes in the aggregate customer discount accrual related to sales in the United States is as follows:

*($ in millions)*

| ​ ​ | ​ | ​ ​ Year Ended December 31, 2024 | ​ | ​ ​ 2023 | ​ | ​ ​ 2022 |
| --- | --- | ---: | --- | ---: | --- | ---: |
| Balance January 1 | ​ | $504 | ​ | $385 | ​ | $329 |
| Provision | ​ | ​ 3,024 | ​ | ​ 2,640 | ​ | ​ 2,221 |
| Payments (1) |  | ​ (3,048) |  | ​ (2,521) |  | ​ (2,165) |
| Balance December 31 | ​ | $480 | ​ | $504 | ​ | $385 |

(1) Includes $48 million of liabilities assumed as part of the Dermavant acquisition.

Accruals for chargebacks are reflected as a direct reduction to accounts receivable and accruals for rebates as current liabilities. The accrued balances relative to these provisions included in accounts receivable and accrued and other current liabilities were $100 million and $380 million, respectively, at December 31, 2024, $87 million and $417 million, respectively, at December 31, 2023 and $78 million and $307 million, respectively, at December 31, 2022. The increase in accrued rebates in 2023 is attributable to a wholesaler buy-in in conjunction with the exit of the interim operating model with Merck for the *Follistim* product.

Outside of the United States, variable consideration in the form of discounts and rebates is a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates. In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government’s total unbudgeted spending and our specific payback obligation. Rebates may also be required based on specific product sales thresholds. We apply an estimated factor against our actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.

We maintain a returns policy that allows our customers in certain countries to return product within a specified period prior to and subsequent to the expiration date (generally, three to six months before and 12 months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, we consider factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic competition, changes in formularies or launch of over-the-counter products, among others.

See Note 2 “Summary of Accounting Policies” to the Consolidated Financial Statements included in this report for additional details on our revenue recognition policy.

#### Contingencies and Environmental Liabilities

We are involved in various claims and legal proceedings of a nature considered normal to our business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. See Note 18 “Contingencies” to the Consolidated Financial Statements included in this report. We record accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated.

Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.

We believe that there are no compliance issues associated with applicable environmental laws and regulations that would have a material adverse effect on us. Expenditures for remediation and environmental liabilities were $3 million in 2024, and are estimated at $14 million in the aggregate for the years 2025 through 2029. Liabilities for all environmental matters that are probable and reasonably estimable have been accrued and totaled $16 million and $19 million at December 31, 2024 and 2023, respectively. These liabilities are undiscounted, do not consider potential recoveries from other parties and will be paid out over the periods of remediation for the applicable sites, which are expected to occur primarily over the next 13 years. Although it is not possible to predict with certainty the outcome of these matters, or the ultimate costs of remediation, we do not believe that any reasonably possible expenditures that may be incurred in excess of the liabilities accrued should exceed $23 million in the aggregate. We also do not believe that these expenditures should result in a material adverse effect on our financial condition, results of operations or liquidity for any year.

#### Impairments of Long-Lived Assets

We assess changes in economic, regulatory and legal conditions and make assumptions regarding estimated future cash flows in evaluating the value of our property, plant and equipment, goodwill and intangible assets. The judgments made in evaluating impairment of long-lived intangibles can materially affect our results of operations.

We periodically evaluate whether current facts or circumstances indicate that the carrying values of our long-lived assets to be held and used may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value. If quoted market prices are not available, we estimate fair value using a discounted value of estimated future cash flows approach.

Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. Goodwill is evaluated for impairment as of October 1 each year, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that fair value is less than carrying value. Some of the factors considered in the assessment include general macroeconomic conditions, conditions specific to the industry and market, cost factors which could have a significant effect on earnings or cash flows, and overall financial performance. If we conclude it is more likely than not that fair value is less than carrying value, a quantitative fair value test is performed. If carrying value is greater than fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill). We completed the annual qualitative goodwill impairment test as of October 1, 2024 and concluded that there was no impairment to goodwill as the fair value of the reporting unit was significantly in excess of the carrying value.

Intangible assets are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives. When events or circumstances warrant a review, we will assess recoverability from future operations using pretax undiscounted cash flows derived from the lowest appropriate asset groupings. Potential risks leading to impairment could include LOE occurring earlier than expected, competition, pricing reductions, and other macroeconomic changes. Impairments are recognized in operating results to the extent that the carrying value of the intangible asset exceeds its fair value, which is determined based on the net present value of estimated future cash flows. We did not have impairment charges as of December 31, 2024 and 2023. We recorded impairment charges of $9 million as of December 31, 2022. See Note 11 “Intangibles” to the Consolidated Financial Statements included in this report for additional details on Intangibles.

#### Taxes on Income

Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. We establish valuation allowances for our deferred tax assets when the amount of expected future income is not likely to support the use of the deduction or credit. We evaluate tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, we recognize the largest amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, we do not recognize any portion of the benefit in the financial statements. We recognize interest and penalties associated with uncertain tax positions as a component of *Taxes on Income* in the consolidated statement of income.

#### Inventory Valuation

Inventories consist of currently marketed products and are valued at the lower of cost or net realizable value. Inventories are assessed regularly for impairment and valuation reserves are established when necessary based on a number of factors including, but not limited to, product obsolescence and changes in estimates of future product demand and expiry. The determination of events and the assumptions utilized in our quantification of valuation reserves may require judgment. No material adjustments have been required to our inventory reserve estimates for the periods presented. Adverse changes in assumptions utilized in our inventory reserve calculations could result in an increase to our inventory valuation reserves and higher cost of sales.

#### Acquisitions

Business combinations are evaluated in order to determine whether transactions should be accounted for as acquisitions of assets or businesses. We make certain judgments, which include assessment of the inputs, processes, and outputs associated with the acquired set of activities. If we determine that substantially all of the fair value of gross assets included in a transaction is concentrated in a single asset (or a group of similar assets), we account for the transaction as an asset acquisition. In an asset acquisition, acquired in-process research and development (“IPR&D”) with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date. Product development milestones are recognized upon achievement and sales-based milestones are recognized when the milestone is deemed probable of being achieved. No goodwill is recorded in an asset acquisition.

To be considered a business, the assets in a transaction need to include an input and a substantive process that together significantly contribute to the ability to create outputs. Businesses acquired are consolidated upon obtaining control. The fair value of assets acquired and liabilities assumed are recognized at the date of acquisition. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Any excess of the purchase price over the estimated fair values of the net assets acquired is recognized as goodwill. Business acquisition costs are expensed when incurred.

The fair values of identifiable intangible assets related to currently marketed products are primarily determined by using an income approach through which fair value is estimated based on each asset’s discounted projected net cash flows. Our estimates of market participant net cash flows consider historical and projected pricing, margins and expense levels; the performance of competing products and the current and expected competition environment where applicable; relevant industry and product growth drivers and factors; product life cycles; the ability to obtain additional marketing and regulatory approvals; the ability to manufacture and commercialize the products; and the life of each asset’s underlying patent and related patent term extension, if any. The net cash flows are then discounted to present value utilizing an appropriate discount rate.

The fair values of identifiable intangible assets related to IPR&D are also determined using an income approach, through which fair value is estimated based on each asset’s probability-adjusted future net cash flows, which reflect the different stages of development of each product and the associated probability of successful completion. The net cash flows are then discounted to present value using an appropriate discount rate. Amounts allocated to acquired IPR&D are capitalized and accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&D project, we will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated and begin amortization.

Certain of our business combinations involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. The fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings in Other expense, net. Changes in any of the inputs may result in a significantly different fair value adjustment.

#### Pension

Our pension plans are calculated using actuarial assumptions including a discount rate for plan benefit obligations and an expected rate of return on plan assets. These significant assumptions are reviewed annually and are disclosed in Note 14 “Pension and Other Postretirement Benefit Plans” to the Consolidated Financial Statements included in this report.

For our pension plans, the discount rate is evaluated on measurement dates to reflect the prevailing market rate of a portfolio of high-quality fixed-income debt instruments that would provide the future cash flows needed to pay the benefits included in the benefit obligation as they come due.

The expected rate of return for the pension plans represents the average rate of return to be earned on plan assets over the period the benefits included in the benefit obligation are to be paid. In developing the expected rate of return, we consider long-term compound annualized returns of historical market data, current market conditions and actual returns on our plan assets. Using this reference information, we develop forward-looking return expectations for each asset category and a weighted-average expected long-term rate of return for a target portfolio allocated across these investment categories. The expected portfolio performance reflects the contribution of active management as appropriate.

#### Stock-Based Compensation

We expense all stock-based payment awards to employees, including grants of stock options, over the requisite service period based on the grant date fair value of the awards. The fair value of certain stock-based awards is determined using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options.

### Recently Issued Accounting Standards

For a discussion of recently issued accounting standards, see Note 2 “Summary of Accounting Policies” to the Consolidated Financial Statements included in this report.

## Controls and procedures

As filed, 39,602 characters.

### Overview

After concerns regarding the Company’s sales practices for wholesalers for *Nexplanon* were brought to the Board’s attention, the Audit Committee oversaw an independent, internal investigation into these sales practices. The Audit Committee’s investigation focused on the Company’s sales of *Nexplanon* to wholesalers. The investigation found that the Company asked two wholesalers in the United States to purchase greater quantities of *Nexplanon* during the Relevant Periods than they otherwise would have purchased based on wholesaler demand. In certain instances, the Company waived inventory management fee performance metrics associated with caps on days of inventory to allow wholesalers to be paid the inventory management fees they would have earned but for the Company’s ask to purchase additional inventory. As a result of these purchases, the United States wholesalers significantly decreased or even halted their purchases of *Nexplanon* during the early weeks of the following quarters until their days of inventory on hand were reduced to levels within the contractual range. Although the incremental amount of *Nexplanon* sales that occurred during the Relevant Periods represented less than 1% of the Company’s consolidated revenue for the year ended December 31, 2022 or December 31, 2024, as applicable (and less than 2% of the Company’s consolidated revenue for the relevant quarterly periods), based on the results of the investigation, the Company has determined that without these sales practices, the Company’s consolidated revenue for the fiscal year ended December 31, 2024 reported in the Original Form 10-K (and certain of the other Relevant Periods) would have fallen short of the Company’s guidance range and/or certain external revenue expectations.

Based on the results of the Audit Committee’s investigation as further set forth in the “Explanatory Note”, the Company determined that these sales practices for wholesalers involving *Nexplanon* in the United States during the Relevant Periods were improper, and that certain of the Company’s prior disclosures relating to these sales practices for wholesalers and their effect upon revenues and product demand in its periodic filings were inaccurate or incomplete, including certain disclosures in the Original Form 10-K that are being amended by this Amendment. As also discussed in the “Explanatory Note”, the Company identified material weaknesses in its internal control over financial reporting, which are described below.

### Evaluation of Disclosure Controls and Procedures (Restated and Amended)

We have established disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act) to provide reasonable assurance that information required to be disclosed in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our Interim Chief Executive Officer (“CEO”) (our principal executive officer) and Chief Financial Officer (“CFO”) (our principal financial officer), as appropriate to allow timely decisions regarding required disclosure, and ensure that information required to be disclosed in the reports we file or submit is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms.

Our management, with the participation of our Interim CEO and CFO, re-evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2024 in connection with the filing of this Amendment. At the time that the Original 10-K was filed on February 28, 2025, our former CEO and CFO had concluded that our disclosure controls and procedures were effective as of December 31, 2024. Based on this subsequent evaluation, the Company’s Interim CEO and CFO have concluded that our disclosure controls and procedures were not effective as of December 31, 2024, due to the material weaknesses in internal control over financial reporting described below.

Notwithstanding the material weaknesses described below, management has concluded that its consolidated financial statements included in the Original Form 10-K, which are also included in their entirety in this Amendment (without restatement or revision of such previously issued consolidated financial statements), continue to fairly present, in all material respects, our financial position and results as of December 31, 2024 and 2023, and as of and for each of the years in the three-year period ended December 31, 2024.

### Management’s Report on Internal Control Over Financial Reporting (Restated and Amended)

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

Management conducted an evaluation of the effectiveness of internal control over financial reporting as of December 31, 2024 based on the framework in Internal Control — Integrated Framework issued in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) (“COSO Framework”).

Based on this evaluation, we identified the following material weaknesses in the Company’s internal control over financial reporting:

- The Company failed to set an appropriate tone at the top. Specifically, our former CEO and leader of the Company’s U.S. commercial organization applied inappropriate pressure to achieve sales targets through sales of *Nexplanon* to two United States wholesalers above demand and engaged in inappropriate business conduct that violated the Company’s Code of Conduct.
- The material weakness with respect to our tone at the top contributed to an additional material weakness of not maintaining effective controls related to information and communication. The Company did not design and maintain effective controls related to the information and communication component of the COSO Framework. Specifically, the former CEO and certain senior members of the Company’s U.S. commercial organization did not ensure appropriate communication with, or provide complete information to, the Company’s Disclosure Committee and the financial reporting group to evaluate disclosures and financial reporting conclusions related to sales practices for wholesalers.

These material weaknesses did not result in misstatements of our previously reported historical consolidated financial statements, including those filed with the Original Form 10-K. Each of these material weaknesses could result in a misstatement of substantially all account balances or disclosures that would result in a material misstatement to our annual or interim consolidated financial statements that would not be prevented or detected.

In Management’s Report on Internal Control Over Financial Reporting included in our Original 10-K for the year ended December 31, 2024, our management, including our former CEO and our CFO, concluded that our internal control over financial reporting was effective as of December 31, 2024. Management subsequently concluded that the material weaknesses described above existed as of December 31, 2024. As a result, management has concluded that the Company did not maintain effective internal control over financial reporting as of December 31, 2024 based on the criteria in the COSO Framework. Accordingly, management has restated its report on internal control over financial reporting.

The effectiveness of the Company’s internal control over financial reporting as of December 31, 2024 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which appears under Item 8 of this Amendment.

### Remediation Plan and Activities

To address the material weaknesses in internal control over financial reporting, the Company, with the oversight of its Audit Committee, has developed a remediation plan, which is described below. We are in the process of implementing measures designed to improve our internal control over financial reporting and remediate the control deficiencies that led to the material weaknesses described above. Actions taken to date include:

- The appointment of a new Interim CEO, the termination and appointment of a new Head of U.S. Commercial & Government Affairs, the appointment of an Executive Chair and the appointment of a Lead Independent Director.

In addition to the remedial actions taken to date, the Company is taking, or plans to take, the following actions, among others, to remediate the material weaknesses identified herein:

- Enhance the Company’s Code of Conduct to clarify responsibilities related to the Company’s financial reporting and disclosures, including awareness of the options to raise concerns or questions to management, human resources, compliance, legal, the technical accounting department and/or through the SpeakUp Tool, which is available globally as an alternate, confidential channel for raising concerns;
- Enhance compliance training and communication on the Company’s Code of Conduct regarding ethical tone and corporate culture and enhance training for commercial and finance personnel regarding appropriate business practices;
- Enhance the Company’s Annual Ethics and Policy Certifications;
- Implement additional representations within the Company’s Quarterly Financial Certification Questionnaire relating to the disclosures of misleading business practices;
- Enhance existing Disclosure Committee responsibilities to include among other requirements, additional questions and more information regarding the representations being made, and provide incremental training on these responsibilities;
- Implement additional and enhance existing sub-certifications and internal management representation letters, including providing training on the purpose of the sub-certification and the process for evaluating the representations;
- Enhance controls and implement written policies and procedures to provide governance, oversight and guidelines for timely communication of management fee arrangements with wholesalers; and
- Evaluate and enhance internal controls related to sales monitoring.

Management continues to evaluate the effectiveness of these remedial measures and expects to continue implementing improvements to the Company’s internal control over financial reporting. The process of designing and maintaining effective internal control over financial reporting is a continuous effort that requires management to anticipate and react to changes in our business, economic, and regulatory environments and to expend significant resources. As we continue to evaluate our internal control over financial reporting, we may take additional actions to remediate the material weaknesses or modify the remediation actions described above.

### Changes in Internal Control Over Financial Reporting

During the fourth quarter of 2024, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

### Part IV

### Items 15. Exhibits and Financial Statement Schedules

### (a) The following documents are filed as part of this report:

**1. Financial Statements: The following financial statements are included in Part II, Item 8 of this Annual Report on Form 10-K.**

- Report of Independent Registered Public Accounting Firm
- Consolidated Statement of Income and Consolidated Statement of Comprehensive Income
- Consolidated Balance Sheet
- Consolidated Statement of Equity
- Consolidated Statement of Cash Flows
- Notes to the Consolidated Financial Statements

### 2\. Exhibits: See Item 15(b) below.

### (b) Exhibits

The exhibits listed on the Exhibit Index beginning on page 68, which is incorporated herein by reference, are filed or furnished as part of this Amendment or are incorporated into this Amendment by reference.

| ​ Number | ​ ​ | ​ Description |
| ---: | ---: | --- |
| 2.1 | — | Separation and Distribution Agreement, dated as of June 2, 2021, by and between Merck & Co., Inc. and Organon & Co. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K (File No. 001-40235) filed on June 3, 2021) |
| 3.1 | — | Amended and Restated Certificate of Incorporation of Organon & Co. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-40235) filed on June 3, 2021) |
| 3.2 | — | Amended and Restated Bylaws of Organon & Co. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-40235) filed on December 9, 2022) |
| 4.1 | — | Form of Specimen Common Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Company’s Annual Report on Form 10-K (File No. 001-40235) filed on March 21, 2022) |
| 4.2 | — | Description of Registrant’s Securities (incorporated herein by reference to Exhibit 4.2 to the Company’s Annual Report on Form 10-K (File No. 001-40235) filed on March 21, 2022) |
| 4.3 | — | Indenture, dated as of April 22, 2021, among Organon Finance 1 LLC, Organon Foreign Debt Co-Issuer B.V., U.S. Bank National Association, as trustee and collateral agent, and Elavon Financial Services DAC, UK Branch, as principal paying agent, transfer agent and registrar, with respect to 2.875% Senior Secured Notes due 2028 (incorporated by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K (File No. 001-40235) filed on June 3, 2021) |
| 4.4 | — | Form of 2.875% Senior Secured Notes due 2028 (incorporated by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K (File No. 001-40235) filed on June 3, 2021) |
| 4.5 | — | Indenture, dated as of April 22, 2021, among Organon Finance 1 LLC, Organon Foreign Debt Co-Issuer B.V. and U.S. Bank National Association, as trustee and collateral agent, with respect to 4.125% Senior Secured Notes due 2028 (incorporated by reference to Exhibit 10.6 to the Company’s Current Report on Form 8-K (File No. 001-40235) filed on June 3, 2021) |
| 4.6 | — | Form of 4.125% Senior Secured Notes due 2028 (incorporated by reference to Exhibit 10.6 to the Company’s Current Report on Form 8-K (File No. 001-40235) filed on June 3, 2021) |
| 4.7 | — | Indenture, dated as of April 22, 2021, among Organon Finance 1 LLC, Organon Foreign Debt Co-Issuer B.V. and U.S. Bank National Association, as trustee, with respect to 5.125% Senior Notes due 2031 (incorporated by reference to Exhibit 10.7 to the Company’s Current Report on Form 8-K (File No. 001-40235) filed on June 3, 2021) |

68

|  |  |  |
| ---: | ---: | --- |
| 4.8 | — | Form of 5.125% Senior Notes due 2031 (incorporated by reference to Exhibit 10.7 to the Company’s Current Report on Form 8-K (File No. 001-40235) filed on June 3, 2021) |
| 4.9 | — | First Supplemental Indenture, dated as of June 2, 2021, among Organon & Co., Organon Foreign Debt Co-Issuer B.V., Organon Finance 1 LLC and U.S. Bank National Association, as trustee and collateral agent, with respect to 2.875% Senior Secured Notes due 2028 (incorporated by reference to Exhibit 10.8 to the Company’s Current Report on Form 8-K (File No. 001-40235) filed on June 3, 2021) |
| 4.10 | — | First Supplemental Indenture, dated as of June 2, 2021, among Organon & Co., Organon Foreign Debt Co-Issuer B.V., Organon Finance 1 LLC and U.S. Bank National Association, as trustee and collateral agent, with respect to 4.125% Senior Secured Notes due 2028 (incorporated by reference to Exhibit 10.9 to the Company’s Current Report on Form 8-K (File No. 001-40235) filed on June 3, 2021) |
| 4.11 | — | First Supplemental Indenture, dated as of June 2, 2021, among Organon & Co., Organon Foreign Debt Co-Issuer B.V., Organon Finance 1 LLC and U.S. Bank National Association, as trustee, with respect to 5.125% Senior Notes due 2031 (incorporated by reference to Exhibit 10.10 to the Company’s Current Report on Form 8-K (File No. 001-40235) filed on June 3, 2021) |
| 4.12 | — | Second Supplemental Indenture, dated as of June 2, 2021, among Organon LLC, Organon Global Inc., Organon Trade LLC, Organon Pharma Holdings LLC, Organon USA LLC, Organon Canada Holdings LLC, Organon & Co., Organon Foreign Debt Co-Issuer B.V. and U.S. Bank National Association, as trustee and collateral agent, with respect to 2.875% Senior Secured Notes due 2028 (incorporated by reference to Exhibit 10.11 to the Company’s Current Report on Form 8-K (File No. 001-40235) filed on June 3, 2021) |
| 4.13 | — | Second Supplemental Indenture, dated as of June 2, 2021, among Organon LLC, Organon Global Inc., Organon Trade LLC, Organon Pharma Holdings LLC, Organon USA LLC, Organon Canada Holdings LLC, Organon & Co., Organon Foreign Debt Co-Issuer B.V. and U.S. Bank National Association, as trustee and collateral agent, with respect to 4.125% Senior Secured Notes due 2028 (incorporated by reference to Exhibit 10.12 to the Company’s Current Report on Form 8-K (File No. 001-40235) filed on June 3, 2021) |
| 4.14 | — | Second Supplemental Indenture, dated as of June 2, 2021, among Organon LLC, Organon Global Inc., Organon Trade LLC, Organon Pharma Holdings LLC, Organon USA LLC, Organon Canada Holdings LLC, Organon & Co., Organon Foreign Debt Co-Issuer B.V. and U.S. Bank National Association, as trustee, with respect to 5.125% Senior Notes due 2031 (incorporated by reference to Exhibit 10.13 to the Company’s Current Report on Form 8-K (File No. 001-40235) filed on June 3, 2021) |
| 4.15 | — | Third Supplemental Indenture, dated as of July 30, 2021, among Organon LLC, Organon Global Inc., Organon Trade LLC, Organon Pharma Holdings LLC, Organon USA LLC, Organon Canada Holdings LLC, Organon & Co., Organon Foreign Debt Co-Issuer B.V. and U.S. Bank National Association, as trustee and collateral agent, with respect to 2.875% Senior Secured Notes due 2028 (incorporated herein by reference to Exhibit 4.15 to the Company’s Form 10-K (File No. 00140235) filed on February 28, 2025) |
| 4.16 | — | Third Supplemental Indenture, dated as of July 30, 2021, among Organon LLC, Organon Global Inc., Organon Trade LLC, Organon Pharma Holdings LLC, Organon USA LLC, Organon Canada Holdings LLC, Organon & Co., Organon Foreign Debt Co-Issuer B.V. and U.S. Bank National Association, as trustee and collateral agent, with respect to 4.125% Senior Secured Notes due 2028 (incorporated herein by reference to Exhibit 4.16 to the Company’s Form 10-K (File No. 00140235) filed on February 28, 2025) |
| 4.17 | — | Third Supplemental Indenture, dated as of July 30, 2021, among Organon LLC, Organon Global Inc., Organon Trade LLC, Organon Pharma Holdings LLC, Organon USA LLC, Organon Canada Holdings LLC, Organon & Co., Organon Foreign Debt Co-Issuer B.V. and U.S. Bank National Association, as trustee, with respect to 5.125% Senior Notes due 2031 (incorporated herein by reference to Exhibit 4.17 to the Company’s Form 10-K (File No. 00140235) filed on February 28, 2025) |
| 4.18 | — | Fourth Supplemental Indenture, dated as of December 31, 2024, among Organon & Co., Organon 2 LLC, Organon Pharma Holdings II LLC, Organon Finance LLC, and (v) Organon International LLC, the subsidiary guarantors party thereto, Dermavant Sciences, Inc., and U.S. Bank Trust Company, National Association, as trustee and collateral agent, with respect to 2.875% Senior Secured Notes due 2028 (incorporated herein by reference to Exhibit 4.18 to the Company’s Form 10-K (File No. 00140235) filed on February 28, 2025) |
| 4.19 | — | Fourth Supplemental Indenture, dated as of December 31, 2024, among Organon & Co., Organon 2 LLC, Organon Pharma Holdings II LLC, Organon Finance LLC, and (v) Organon International LLC, the subsidiary guarantors party thereto, Dermavant Sciences, Inc., and U.S. Bank Trust Company, National Association, as trustee and collateral agent, with respect to 4.125% Senior Secured Notes due 2028 (incorporated herein by reference to Exhibit 4.19 to the Company’s Form 10-K (File No. 00140235) filed on February 28, 2025) |
| 4.20 | — | Fourth Supplemental Indenture, dated as of December 31, 2024, among Organon & Co., Organon 2 LLC, Organon Pharma Holdings II LLC, Organon Finance LLC, and (v) Organon International LLC, the subsidiary guarantors party thereto, Dermavant Sciences, Inc., and U.S. Bank Trust Company, National Association, as trustee, with respect to 5.125% Senior |

69

|  |  | Notes due 2031 (incorporated herein by reference to Exhibit 4.20 to the Company’s Form 10-K (File No. 00140235) filed on February 28, 2025) |
| --- | ---: | --- |
| 4.21 | — | Indenture, dated as of May 17, 2024, by and among Organon & Co., Organon Foreign Debt Co-Issuer B.V., the subsidiary guarantors party thereto, and U.S. Bank Trust Company, National Association, as trustee and collateral agent, with respect to 6.750% Senior Secured Notes Due 2034 (incorporated herein by reference to Exhibit 4.1 to the Company’s Form 8-K (File No. 001-40235) filed on May 17, 2024) |
| 4.22 | — | Form of 6.750% Senior Secured Notes due 2034 (incorporated herein by reference to Exhibit 4.1 to the Company’s Form 8-K (File No. 001-40235) filed on May 17, 2024) |
| 4.23 | — | Indenture, dated as of May 17, 2024, by and among Organon & Co., Organon Foreign Debt Co-Issuer B.V., the subsidiary guarantors party thereto, and U.S. Bank Trust Company, National Association, as trustee, with respect to 7.875% Senior Notes Due 2034 (incorporated herein by reference to Exhibit 4.3 to the Company’s Form 8-K (File No. 001-40235) filed on May 17, 2024) |
| 4.24 | — | Form of 7.875% Senior Notes due 2034 (incorporated herein by reference to Exhibit 4.3 to the Company’s Form 8-K (File No. 001-40235) filed on May 17, 2024) |
| 4.25 | — | First Supplemental Indenture, dated as of December 31, 2024, among Organon & Co., Organon 2 LLC, Organon Pharma Holdings II LLC, Organon Finance LLC, and (v) Organon International LLC, the subsidiary guarantors party thereto, Dermavant Sciences, Inc., and U.S. Bank Trust Company, National Association, as trustee and collateral agent, with respect to 6.750% Senior Secured Notes due 2034 (incorporated herein by reference to Exhibit 4.25 to the Company’s Form 10-K (File No. 00140235) filed on February 28, 2025) |
| 4.26 | — | First Supplemental Indenture, dated as of December 31, 2024, among Organon & Co., Organon 2 LLC, Organon Pharma Holdings II LLC, Organon Finance LLC, and (v) Organon International LLC, the subsidiary guarantors party thereto, Dermavant Sciences, Inc., and U.S. Bank Trust Company, National Association, as trustee, with respect to 7.875% Senior Notes due 2034 (incorporated by reference to Exhibit 4.26 to the Company’s Annual Report on Form 10-K (File No. 001-40235) filed on February 28, 2025) |
| †10.1 | — | Tax Matters Agreement, dated as of June 2, 2021, by and between Merck & Co., Inc. and Organon & Co. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-40235) filed on June 3, 2021) |
| 10.2 | — | Employee Matters Agreement, dated as of June 2, 2021, by and between Merck & Co., Inc. and Organon & Co. (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K (File No. 001-40235) filed on June 3, 2021) |
| †10.3 | — | Transition Services Agreement, dated as of June 2, 2021, by and between Merck & Co., Inc. and Organon & Co. (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K (File No. 001-40235) filed on June 3, 2021) |
| †10.4 | — | Transition Services Agreement, dated as of June 2, 2021, by and between Merck & Co., Inc. and Organon & Co. (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K (File No. 001-40235) filed on June 3, 2021) |
| †10.5 | — | Senior Secured Credit Agreement, dated as of June 2, 2021, by and among Organon & Co., Organon Foreign Debt Co-Issuer B.V., JPMorgan Chase Bank, N.A., as Administrative Agent, Collateral Agent, and the L/C Issuers and Lenders party thereto (incorporated by reference to Exhibit 10.14 to the Company’s Current Report on Form 8-K (File No. 001-40235) filed on June 3, 2021) |
| †10.6 | — | Amendment No. 1 to Senior Secured Credit Agreement, dated as of June 30, 2023, to the Credit Agreement by and among Organon & Co., Organon Foreign Debt Co-Issuer B.V., JPMorgan Chase Bank, N.A., as Administrative Agent, Collateral Agent, and the L/C Issuers and Lenders party thereto (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-40235) filed on July 7, 2023). |
| †10.7 | — | Amendment No. 2 to Senior Secured Credit Agreement, dated as of May 17, 2024, by and among Organon & Co., Organon Foreign Debt Co-Issuer B.V., the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-40235) filed on May 17, 2024) |
| †10.8 | — | Amendment No. 3 to Senior Secured Credit Agreement, dated as of December 20, 2024, Organon & Co., Organon Foreign Debt Co-Issuer B.V., the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent (incorporated herein by reference to Exhibit 10.8 to the Company’s Form 10-K (File No. 00140235) filed on February 28, 2025) |
| +10.9 | — | Form of Indemnification Agreement (incorporated by reference to Exhibit 10.15 to the Company’s Current Report on Form 8-K (File No. 001-40235) filed on June 3, 2021) |
| +10.10 | — | Organon & Co. 2021 Incentive Stock Plan (incorporated by reference to Exhibit 10.16 to the Company’s Current Report on Form 8-K (File No. 001-40235) filed on June 3, 2021) |
| +10.11 | — | Organon & Co. Annual Incentive Plan (incorporated by reference to Exhibit 10.17 to the Company’s Current Report on Form 8-K (File No. 001-40235) filed on June 3, 2021) |

70

|  |  |  |
| --- | ---: | --- |
| +10.12 | — | Organon & Co. Executive Change in Control Severance Program (incorporated by reference to Exhibit 10.18 to the Company’s Current Report on Form 8-K (File No. 001-40235) filed on June 3, 2021) |
| +10.13 | — | Organon & Co. Executive Severance Program (incorporated by reference to Exhibit 10.19 to the Company’s Current Report on Form 8-K (File No. 001-40235) filed on June 3, 2021) |
| +10.14 | — | Organon & Co. Executive Severance Program, as amended and restated on February 8, 2024. (incorporated by reference to Exhibit 10.21 to the Company’s Annual Report on Form 10-K (File No. 001-40235) filed on February 26, 2024) |
| +10.15 | — | Organon Non-Employee Director Savings Plan, as amended and restated on January 1, 2025 (incorporated herein by reference to Exhibit 10.15 to the Company’s Form 10-K (File No. 00140235) filed on February 28, 2025) |
| +10.16 | — | Development and Commercialization Agreement by and between Samsung Bioepis Co., Ltd., and Merck Sharp & Dohme Corp., dated February 18, 2013 (incorporated by reference to Exhibit 10.4 to Organon’s Registration Statement on Form 10 (File No. 001-40235) filed on April 14, 2021) |
| +10.17 | — | Amendment No. 1 to Development and Commercialization Agreement by and between Samsung Bioepis Co., Ltd., and Merck Sharp & Dohme Corp., dated July 21, 2014 (incorporated by reference to Exhibit 10.5 to Organon’s Registration Statement on Form 10 (File No. 001-40235) filed on April 14, 2021) |
| +10.18 | — | Amendment No. 2 to Development and Commercialization Agreement by and between Samsung Bioepis Co., Ltd., and Merck Sharp & Dohme Corp., dated August 2, 2017 2014 (incorporated by reference to Exhibit 10.6 to Organon’s Registration Statement on Form 10 (File No. 001-40235) filed on April 14, 2021) |
| +10.19 | — | Amendment No. 3 to Development and Commercialization Agreement by and between Samsung Bioepis Co., Ltd., and Merck Sharp & Dohme Corp., dated October 1, 2017 (incorporated by reference to Exhibit 10.7 to Organon’s Registration Statement on Form 10 (File No. 001-40235) filed on April 14, 2021) |
| +10.20 | — | Amendment No. 4 to Development and Commercialization Agreement by and between Samsung Bioepis Co., Ltd., and Merck Sharp & Dohme Corp., dated September 1, 2018 (incorporated by reference to Exhibit 10.8 to Organon’s Registration Statement on Form 10 (File No. 001-40235) filed on April 14, 2021) |
| +10.21 | — | Amendment No. 5 to Development and Commercialization Agreement by and between Samsung Bioepis Co., Ltd., and Merck Sharp & Dohme Corp., dated October 15, 2018 (incorporated by reference to Exhibit 10.9 to Organon’s Registration Statement on Form 10 (File No. 001-40235) filed on April 14, 2021) |
| +10.22 | — | Amendment No. 6 to Development and Commercialization Agreement by and between Samsung Bioepis Co., Ltd., and Merck Sharp & Dohme Corp., dated December 19, 2018 (incorporated by reference to Exhibit 10.10 to Organon’s Registration Statement on Form 10 (File No. 001-40235) filed on April 14, 2021) |
| +10.23 | — | Amendment No. 7 to Development and Commercialization Agreement by and between Samsung Bioepis Co., Ltd., and Merck Sharp & Dohme Corp., dated May 15, 2020 (incorporated by reference to Exhibit 10.11 to Organon’s Registration Statement on Form 10 (File No. 001-40235) filed on April 14, 2021) |
| +10.24 | — | Specified Technology License Agreement (Nexplanon Rod Technology) by and between Merck Sharp & Dohme B.V. and Merck Sharp & Dohme RT B.V., dated October 28, 2020 (incorporated by reference to Exhibit 10.12 to Organon’s Registration Statement on Form 10 (File No. 001-40235) filed on March 17, 2021) |
| +10.25 | — | Letter Agreement between Kevin Ali and Merck & Co., Inc. dated October 14, 2020 (incorporated by reference to Exhibit 10.15 to Organon’s Registration Statement on Form 10 (File No. 001-40235) filed on April 29, 2021) |
| +10.26 | — | Letter Agreement between Matthew M. Walsh and Merck Sharp & Dohme Corp. dated March 24, 2020 (incorporated by reference to Exhibit 10.16 to Organon’s Registration Statement on Form 10 (File No. 001-40235) filed on April 29, 2021) |
| +10.27 | — | Supplemental License Agreement (Nexplanon Rod Technology) by and between Merck Sharp & Dohme B.V. and Merck Sharp & Dohme RT B.V., dated December 13, 2021 (incorporated by reference to Exhibit 10.35 to the Company’s Annual Report on Form 10-K (File No. 001-4023) filed on March 21, 2022) |
| +10.28 | — | Form of Executive Separation Agreement (incorporated by reference to Exhibit 10.38 to the Company’s Annual Report on Form 10-K (File No. 001-40235) filed on February 26, 2024) |
| +10.29 | — | Form of Global Terms for 2024 Non-Qualified Stock Option Grants Under the Organon & Co. 2021 Incentive Stock Plan (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q (File No. 001-40235) filed on August 7, 2024) |
| +10.30 | — | Form of Global Terms for 2024 Performance Stock Unit Award Under the Organon & Co. 2021 Incentive Stock Plan (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q (File No. 001-40235) filed on August 7, 2024) |
| +10.31 | — | Form of Global Terms for 2024 Restricted Stock Unit Award Under the Organon & Co. 2021 Incentive Stock Plan (Stock Default) (incorporated by reference to Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q (File No. 001-40235) filed on August 7, 2024) |
| +10.32 | — | Form of Global Terms for 2024 Restricted Stock Unit Award Under the Organon & Co. 2021 Incentive Stock Plan (Cash Default) (incorporated by reference to Exhibit 10.5 to the Company’s Quarterly Report on Form 10-Q (File No. 001-40235) filed on August 7, 2024) |

71

|  |  |  |
| --- | ---: | --- |
| +10.33 | — | Form of Global Terms for 2025 Non-Qualified Stock Option Grants Under the Organon & Co. 2021 Incentive Stock Plan (incorporated herein by reference to Exhibit 10.33 to the Company’s Form 10-K (File No. 00140235) filed on February 28, 2025) |
| +10.34 | — | Form of Global Terms for 2025 Performance Stock Unit Award Under the Organon & Co. 2021 Incentive Stock Plan (incorporated herein by reference to Exhibit 10.34 to the Company’s Form 10-K (File No. 00140235) filed on February 28, 2025) |
| +10.35 | — | Form of Global Terms for 2025 Restricted Stock Unit Award Under the Organon & Co. 2021 Incentive Stock Plan (Stock Default) (incorporated herein by reference to Exhibit 10.35 to the Company’s Form 10-K (File No. 00140235) filed on February 28, 2025) |
| +10.36 | — | Form of Global Terms for 2025 Restricted Stock Unit Award Under the Organon & Co. 2021 Incentive Stock Plan (Cash Default) (incorporated herein by reference to Exhibit 10.36 to the Company’s Form 10-K (File No. 00140235) filed on February 28, 2025) |
| +10.37 | — | Agreement and Plan of Merger, dated September 17, 2024, by and among Organon & Co., Organon Bermuda Ltd., Dermavant Sciences Ltd. and Roivant Sciences Ltd. (incorporated herein by reference to Exhibit 10.1 to the Company’s Form 8-K (File No. 00140235) filed on September 23, 2024) |
| 19.1 | ​ | Insider Trading Policy (incorporated herein by reference to Exhibit 19.1 to the Company’s Form 10-K (File No. 00140235) filed on February 28, 2025) |
| 21.1 | — | List of Subsidiaries (incorporated herein by reference to Exhibit 21.1 to the Company’s Form 10-K (File No. 00140235) filed on February 28, 2025) |
| \*23.1 | — | Consent of PricewaterhouseCoopers LLP |
| \*24.1 | — | Power of Attorney (included on signature page) |
| \*31.1 | — | Rule 13a-14(a)/15d-14(a) Certification of Interim Chief Executive Officer |
| \*31.2 | — | Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer |
| \*\*32.1 | — | Section 1350 Certification of Interim Chief Executive Officer |
| \*\*32.2 | — | Section 1350 Certification of Chief Financial Officer |
| 97.1 | — | Organon & Co. Dodd-Frank Policy On Recoupment Of Incentive Compensation (incorporated by reference to Exhibit 97.1 to the Company’s Annual Report on Form 10-K (File No. 001-40235) filed on February 26, 2024) |
| 101.INS | — | XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH | — | XBRL Taxonomy Extension Schema Document. |
| 101.CAL | — | XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101.DEF | — | XBRL Taxonomy Extension Definition Linkbase Document. |
| 101.LAB | — | XBRL Taxonomy Extension Label Linkbase Document. |
| 101.PRE | — | XBRL Taxonomy Extension Presentation Linkbase Document. |
| 104 | — | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |

\+ Management contract or compensatory plan or arrangement.

\* Filed herewith.

\*\* Furnished herewith.

† Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant agrees to furnish a copy of any omitted schedule or exhibit to the SEC upon request; provided, however, that the registrant may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any document so furnished.

1 Indicates, in this Annual Report on Form 10-K, as amended, brand names of products, which are not available in the United States.

2 Indicates, in this Annual Report on Form 10-K, as amended, brand names of products, which are registered trademarks not owned by the Company or its subsidiaries. *Prolia* and *Xgeva* are trademarks registered in the U.S. in the name of Amgen Inc.; *Humira* is a trademark registered in the U.S. in the name of AbbVie Biotechnology Ltd.; *Enbrel* is a trademark registered in the U.S. in the name of Immunex Corporation; *Remicade* is a trademark registered in the U.S. in the name of Janssen Biotech, Inc.; *Avastin, Perjeta* and *Herceptin* are trademarks registered in the U.S. in the name of Genentech, Inc.; *Clarinex* is a trademark registered in the U.S. in the name of Bayer Healthcare LLC (used under license); *Emgality* is a trademark registered in the U.S. in the name of Eli Lilly and Company (used under license); and *Rayvow* is a registered trademark of Eli Lilly in the European Union and other countries (used under license). Brand names of products that are in all italicized letters, without the footnote, are registered trademarks of Organon and/or one of its subsidiaries.

#### Signatures

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

|  |  |
| --- | --- |
| ​ | ​ |
| ​ | ORGANON & CO. |
| ​ | ​ |
| Date: November 10, 2025 | /s/ Matthew Walsh |
| ​ | Matthew Walsh |
| ​ | Chief Financial Officer |

We, the undersigned directors and officers of Organon, hereby severally constitute Joseph Morrissey and Matthew Walsh, and each of them singly, our true and lawful attorneys with full power to them and each of them to sign for us, in our names in the capacities indicated below, any and all amendments to this Annual Report on Form 10-K filed with the Securities and Exchange Commission.

Pursuant to the requirements of the Securities and Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ​ | ​ | ​ | ​ | ​ |
| **SIGNATURE** |  | **TITLE** |  | **DATE** |
| /s/ Joseph Morrissey | ​ | Interim Chief Executive Officer (Principal Executive Officer) | ​ | November 10, 2025 |
| /s/ Matthew Walsh | ​ | Chief Financial Officer (Principal Financial and Accounting Officer) | ​ | November 10, 2025 |
| /s/ Lynette Holzbaur | ​ | Senior Vice President Finance - Corporate Controller | ​ | November 10, 2025 |
| /s/ Carrie Cox | ​ | Executive Chair of the Board of Directors | ​ | November 10, 2025 |
| /s/ Robert Essner | ​ | Lead Independent Director | ​ | November 10, 2025 |
| /s/ Alan Ezekowitz | ​ | Director | ​ | November 10, 2025 |
| /s/ Helene Gayle | ​ | Director | ​ | November 10, 2025 |
| /s/ Rochelle Lazarus | ​ | Director | ​ | November 10, 2025 |
| /s/ Deborah Leone | ​ | Director | ​ | November 10, 2025 |
| /s/ Philip Ozuah | ​ | Director | ​ | November 10, 2025 |
| /s/ Cynthia Patton | ​ | Director | ​ | November 10, 2025 |
| /s/ Grace Puma | ​ | Director | ​ | November 10, 2025 |
| /s/ Ramona Sequeira | ​ | Director | ​ | November 10, 2025 |
| /s/ Shalini Sharp | ​ | Director | ​ | November 10, 2025 |

73

Filed Nov 10, 2025.
Source: SEC EDGAR, the filing index for accession 0001104659-25-108693. Last ingested by Listed: Nov 11, 2026, 00:27 ET. No prices; not investment advice.
